Cargando…
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis
BACKGROUND: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field for decades. Dissatisfaction with existing measures has led to several consensus meetings and initiatives over the past few decades in hopes of defining and gaining acceptan...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826875/ https://www.ncbi.nlm.nih.gov/pubmed/30334474 http://dx.doi.org/10.1177/1352458518808204 |
_version_ | 1783465194588995584 |
---|---|
author | Strober, Lauren DeLuca, John Benedict, Ralph HB Jacobs, Adam Cohen, Jeffrey A Chiaravalloti, Nancy Hudson, Lynn D Rudick, Richard A LaRocca, Nicholas G |
author_facet | Strober, Lauren DeLuca, John Benedict, Ralph HB Jacobs, Adam Cohen, Jeffrey A Chiaravalloti, Nancy Hudson, Lynn D Rudick, Richard A LaRocca, Nicholas G |
author_sort | Strober, Lauren |
collection | PubMed |
description | BACKGROUND: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field for decades. Dissatisfaction with existing measures has led to several consensus meetings and initiatives over the past few decades in hopes of defining and gaining acceptance of measures that are valid, reliable, sensitive to change and progression, and most importantly, relevant to those living with MS. The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed for this purpose. OBJECTIVE: The objective of this paper is to describe the results of the MSOAC plan to obtain qualification for a cognitive performance measure that meets these requirements. METHODS: Using data from 14 MS disease-modifying registration trials, we completed a comprehensive examination of the psychometric qualities of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) with the goal of compiling evidence to support the utilization of one of these measures in future clinical trials. RESULTS AND CONCLUSION: Consistent with the published literature, the SDMT proved superior to the PASAT. The SDMT should be considered the measure of choice for MS trials in assessing cognitive processing speed. |
format | Online Article Text |
id | pubmed-6826875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-68268752019-12-04 Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis Strober, Lauren DeLuca, John Benedict, Ralph HB Jacobs, Adam Cohen, Jeffrey A Chiaravalloti, Nancy Hudson, Lynn D Rudick, Richard A LaRocca, Nicholas G Mult Scler Original Research Papers BACKGROUND: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field for decades. Dissatisfaction with existing measures has led to several consensus meetings and initiatives over the past few decades in hopes of defining and gaining acceptance of measures that are valid, reliable, sensitive to change and progression, and most importantly, relevant to those living with MS. The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed for this purpose. OBJECTIVE: The objective of this paper is to describe the results of the MSOAC plan to obtain qualification for a cognitive performance measure that meets these requirements. METHODS: Using data from 14 MS disease-modifying registration trials, we completed a comprehensive examination of the psychometric qualities of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) with the goal of compiling evidence to support the utilization of one of these measures in future clinical trials. RESULTS AND CONCLUSION: Consistent with the published literature, the SDMT proved superior to the PASAT. The SDMT should be considered the measure of choice for MS trials in assessing cognitive processing speed. SAGE Publications 2018-10-18 2019-11 /pmc/articles/PMC6826875/ /pubmed/30334474 http://dx.doi.org/10.1177/1352458518808204 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Papers Strober, Lauren DeLuca, John Benedict, Ralph HB Jacobs, Adam Cohen, Jeffrey A Chiaravalloti, Nancy Hudson, Lynn D Rudick, Richard A LaRocca, Nicholas G Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title_full | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title_fullStr | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title_full_unstemmed | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title_short | Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
title_sort | symbol digit modalities test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis |
topic | Original Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826875/ https://www.ncbi.nlm.nih.gov/pubmed/30334474 http://dx.doi.org/10.1177/1352458518808204 |
work_keys_str_mv | AT stroberlauren symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT delucajohn symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT benedictralphhb symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT jacobsadam symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT cohenjeffreya symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT chiaravallotinancy symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT hudsonlynnd symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT rudickricharda symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT laroccanicholasg symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis AT symboldigitmodalitiestestavalidclinicaltrialendpointformeasuringcognitioninmultiplesclerosis |